Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Postmenopausal Women
100%
Bone Metabolism
100%
Dasatinib
100%
Senolytic Therapy
100%
Quercetin
100%
Phase 2 Randomized Controlled Trial
100%
Senescent Cells
50%
Senolytics
50%
Cellular Burden
33%
Bone Turnover Markers
33%
Procollagen Type 1 N-terminal Propeptide (P1NP)
33%
Age-related
16%
Aging
16%
T Cells
16%
Clinical Response
16%
Cyclin-dependent Kinase Inhibitor 2A (CDKN2A)
16%
MRNA Level
16%
Bone Loss
16%
Bone Resorption
16%
Bone Mineral Density
16%
Between-group
16%
Serious Adverse Events
16%
Multiple-ages
16%
Intermittent Administration
16%
C-terminal Telopeptide of Type I Collagen
16%
Radius Bone
16%
Medicine and Dentistry
Randomized Controlled Trial
100%
Postmenopause
100%
Dasatinib
100%
Quercetin
100%
Bone Remodeling
100%
Osteolysis
50%
Amino Terminal Sequence
33%
Procollagen
33%
Adverse Event
16%
T Cell
16%
Ossification
16%
Bone Density
16%
P16
16%
Collagen Type 1
16%
C-Terminal Telopeptide
16%
Cyclin Dependent Kinase Inhibitor 2A
16%
Messenger RNA
16%
Biochemistry, Genetics and Molecular Biology
Postmenopause
100%
Bone Remodeling
100%
Randomized Controlled Trial
100%
Dasatinib
100%
Quercetin
100%
Osteolysis
50%
N-Terminus
33%
T Cell
16%
Ossification
16%
P16
16%
Bone Density
16%
Type I Collagen
16%
C-Terminal Telopeptide
16%
Messenger RNA
16%
Cyclin Dependent Kinase Inhibitor 2A
16%
Immunology and Microbiology
Osteolysis
100%
Bone Remodeling
100%
Postmenopause
100%
Amino Terminal Sequence
66%
T Cell
33%
Ossification
33%
Carboxy Terminal Sequence
33%
Bone Density
33%